This invention provides a solubility enhancer for monosodium urate for use in the treatment of gout. The solubility enhancer may be a pharmaceutically acceptable base, a solvent, a lipid, a surfactant, a pharmaceutically acceptable acid, a cyclodextrin, at least one paraben or a combination thereof.